You are using an outdated browser. Please upgrade your browser to improve your experience.

belantamab mafodotin

Ligand Summary
Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
Synonyms & Links
DrugCentral: 5405
LyCHI:  belantamab mafodotin

Target Activities